Affiliation:
1. First Affiliated Hospital of Guangdong Pharmaceutical University
2. Guangdong Pharmaceutical University
Abstract
Abstract
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-induced deaths around the world, and platinum-based chemotherapy remains a standard-of-care for most patients with advanced NSCLC. DNA damage response (DDR) induced by platinum or Etoposide activated a panel of cell cycle-regulatory proteins including p21 through p53 pathway. In this present study, we found that the level of p21 or RanBPM is lower in NSCLC than non-malignant tissues and has a highly positive correlation, which is positively correlated with the survival of patients. We further revealed that RanBPM protein physically interacts with p21, RanBPM deubiquitinates p21 by recruiting a deubiquitinase USP11 to maintain protein stability of p21. Furthermore, RanBPM regulates DNA damage response (DDR) in a p21-dependent manner, and DNA damage promotes the translocation of RanBPM into the nucleus and regulates p21 protein stability through ATM-mediated pathways. We revealed a novel mechanism of p21 protein stability regulated by RanBPM, and the novel roles of RanBPM in the regulation of DDR.
Publisher
Research Square Platform LLC
Reference26 articles.
1. H. Sung, J. Ferlay, R.L. Siegel et al., Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians. 2021;71(3):209–249
2. Non-small-cell lung cancers: a heterogeneous set of diseases;Chen Z;Nat. Rev. Cancer,2014
3. Refining the treatment of NSCLC according to histological and molecular subtypes;Thomas A;Nat. Rev. Clin. Oncol.,2015
4. Platinum-based chemotherapy in advanced non-small-cell lung cancer: optimal number of treatment cycles;Rossi A;Expert Rev. Anticancer Ther.,2016
5. Chemotherapy induced DNA damage response: convergence of drugs and pathways;Woods D;Cancer Biol. Ther.,2013